<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04291859</url>
  </required_header>
  <id_info>
    <org_study_id>18252A</org_study_id>
    <secondary_id>2019-001280-77</secondary_id>
    <nct_id>NCT04291859</nct_id>
  </id_info>
  <brief_title>Lu AF28996 in Participants With Parkinson's Disease (PD)</brief_title>
  <official_title>Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety of Lu AF28996, how well it is&#xD;
      tolerated and what the body does to the drug in participants with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has been re-designed following inclusion of 2 participants. The study will consist&#xD;
      of 4 cohorts (men or women). Cohort 1 is complete and included 2 participants. New&#xD;
      participants will start with Cohort 2. Cohort 2 will consist of 3 participants and Cohorts 3&#xD;
      and 4 will each consist of 4 participants with the possibility of adding 1 more cohort&#xD;
      including 4 participants (Cohort 5).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">July 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events</measure>
    <time_frame>From Baseline to Day 47</time_frame>
    <description>Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight, ECG parameters and physical examination)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(last) of Lu AF28996</measure>
    <time_frame>0 (predose) to 24 hours postdose on Day 1 to Day 16</time_frame>
    <description>Area under the plasma concentration time curve from zero to last quantifiable plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-24h) of Lu AF28996</measure>
    <time_frame>0 (predose) to 24 hours postdose on Day 1 to Day 16</time_frame>
    <description>Area under the plasma concentration time curve from zero to 24 hours post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Lu AF28996</measure>
    <time_frame>0 (predose) to 24 hours postdose on Day 1 to Day 16</time_frame>
    <description>Maximum observed plasma concentration of Lu AF28996</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of Lu AF28996</measure>
    <time_frame>0 (predose) to 24 hours postdose on Day 1 to Day 16</time_frame>
    <description>Oral clearance for Lu AF28996 in plasma</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Lu AF28996</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ascending oral doses of Lu AF28996 once daily for 14 days (Day 1 to Day 14) in all cohorts. On Day 15, the participant will initiate down-titration of Lu AF28996 as per Investigator's judgement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF28996</intervention_name>
    <description>capsule, orally, doses and dose escalation scheme will be decided upon at dosing conferences</description>
    <arm_group_label>Lu AF28996</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women diagnosed with idiopathic PD (consistent with the UK PD Society Brain&#xD;
             Bank Criteria for the Diagnosis of PD), Modified Hoehn and Yahr Score ≤4 in the 'OFF'&#xD;
             state and ≤3 in 'ON' state and a Mini Mental State Examination Score &gt;25.&#xD;
&#xD;
          -  Participants must currently have a good response to levodopa, and has been receiving a&#xD;
             stable dose of levodopa (&gt;3 doses per day of standard levodopa or &gt;3 doses per day of&#xD;
             carbidopa and levodopa, or benserazide and levodopa, Extended-Release Capsules) for at&#xD;
             least 4 weeks prior to screening.&#xD;
&#xD;
          -  Participants must experience recognizable and predictable motor fluctuations (with at&#xD;
             least 1.5 hours of OFF-periods in the awake time, including predictable morning OFF&#xD;
             episodes) causing clinically significant disability during the 4-week screening&#xD;
             period. This will be documented using a participant ON/OFF state registration over 3&#xD;
             consecutive days prior to enrolment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has or has had one or more of the following conditions that are&#xD;
             considered clinically relevant in the context of the study; other neurological&#xD;
             disorder, psychiatric disorder, seizure disorder or encephalopathy, respiratory&#xD;
             disease, hepatic impairment or renal insufficiency, metabolic disorder,&#xD;
             endocrinological disorder, haematological disorder, infectious disorder, any&#xD;
             clinically significant immunological condition, or a history of narrow-angle glaucoma&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>QPS Netherlands BV</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

